A New Treatment for Breast Cancer: Veliparib - Carboplatin

Breast cancer is a group of diseases with clinically and genetically different subtypes. This makes it necessary to identify effective treatments tailored to each patient. New targeted treatment options are needed to improve treatment success in breast cancer.
The tumor-shrinking (neoadjuvant) chemotherapy we give before surgery allows us to observe the patient’s response to chemotherapy. The pathological complete response achieved with neoadjuvant treatment, particularly in the triple-negative group, is directly associated with both disease-free survival and overall survival, in other words, treatment success.
Laboratory studies have shown that the DNA repair-blocking ADP-ribose polymerase (PARP) inhibitor — the new drug Veliparib — significantly increases the effect of carboplatin, one of the standard chemotherapy drugs.
The primary endpoint of the study was pathological complete response, while the secondary endpoints were event-free survival and overall survival. According to the study, in phase III the triple-negative patient group achieved a pathological complete response rate of %51 with the veliparib–carboplatin combination, compared with %26 in the control arm. The most common side effects in the veliparib–carboplatin arm were hematological: neutropenia, thrombocytopenia and anemia.
In conclusion, this study demonstrated that adding veliparib–carboplatin to standard chemotherapy increases the pathological complete response rate in triple-negative breast cancer.
Sources
Adaptive Randomization of Veliparib–Carboplatin Treatment in Breast Cancer.
N Engl J Med. 2016 Jul 7;375(1):23-34. doi: 10.1056/NEJMoa1513749.
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.